Sort publications on year

  • Pharmaco-Economics

    Cost-effectiveness analysis of PMMA, silicone, or acrylic intra-ocular lenses in cataract surgery in four European countries

    SMITH A, LAFUMA A, BERDEAUX G , BERTO P, BRUEGGENJUERGEN B, MAGAZ S, AUFFARTH G, BREZIN A, CAPOROSSI A, MENDICUTE J

    Ophthalmic Epidemiol ; 12(5):343-351

  • Pharmaco-Economics

    Frequency and hospitalisation-related costs of manic episodes in patients with bipolar I disorder in France

    DE ZELICOURT M, DARDENNES R, VERDOUX H, GANDHI G, CHOMETTE E, KHOSHNOOD B, PAPATHEODOROU ML, EDGELL ET, EVEN C, FAGNANI F

    Pharmacoeconomics ; 2003;21(15):1081-1090

  • Pharmaco-Economics

    Effectiveness and cost of contraception in France (FACET study): a cohort study from the French National Healthcare Insurance Database.

    AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD A, LAFUMA A, DOZ M, LEVY-BACHELOT L, GOURMELEN J, LINET T.

    European Journal of Obstetrics & Gynecology and Reproductive Biology ; 2018;229: 137–143

  • Pharmaco-Economics

    Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis.

    CHARBONNEL B, SIMON D, DALLONGEVILLE J, BUREAU I, DEJAGER S, LEVY-BACHELOT L, GOURMELEN J, DETOURNAY B.

    Pharmacoecon Open ; 2018;2(2):209-219

  • Pharmaco-Economics

    Le traitement du diabète de type 2 en France est dynamique plutôt qu’inerte : analyse des prescriptions de 847 122 patients.

    ROUSSEL R, FONTAINE P, GOUET D, SERUSCLAT P, MARTINEZ L, DETOURNAY B, MARTIN-KRISTENSEN M.

    Med Mal Metab ; 2018;12(4):346-352

  • Pharmaco-Economics

    Clinical outcomes of glaucoma Treatments Over a patient lifetime : a Markov Model

    NORDMANN JP, LAFUMA A, DESCHASEAUX-VOINET C, BERDEAUX G

    J Glaucoma ; 14(6):463-469

  • Pharmaco-Economics

    Medical predictive Factors of Glaucoma Treatment Costs

    DENIS P, LAFUMA A, BERDEAUX G

    J Glaucoma ; 13(4):283-290

  • Pharmaco-Economics

    Le point de vue de l’économiste de la santé in “Evaluation des médicaments après la commercialisation – Intérêts, objectifs et conséquence

    FAGNANI F

    John Libbey Eurotext ; 59-62

  • Pharmaco-Economics

    Hepatitis B management costs in France, Italy, Spain, and the United Kingdom

    BROWN RE, DE COCK E, COLIN X, ANTONANZAS F, ILOEJE UH

    J Clin Gastroenterol ; 38(10 Suppl):S169-174

  • Pharmaco-Economics

    Economic evaluation of a combined DTPa, Hepatitis B, Polio, Hib vaccine Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule

    FAGNANI F, LE FUR C, DURAND I, GIBERGY M

    Eur J Health Econom ; 5(2):143-149

  • Pharmaco-Economics

    Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications

    FAGNANI F, LAFUMA A, PECHEVIS M, RIGAUD AS, TRAYKOV L, SEUX ML, FORETTE F

    Dement Geriatr Cogn Disord ; 17(1-2):5-13

  • Pharmaco-Economics

    Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease

    RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FORETTE F

    J Geriatr Psychiatry Neurol ; 16(3):140-145

  • Pharmaco-Economics

    Patients with Alzheimer’s disease living at home in France : costs and consequences of the disease

    RIGAUD AS, FAGNANI F, BAYLE C, LATOUR F, TRAYKOV L, FLORETTE F

    J Geriatr Psychiatry Neurol ; 16(3):140-145

  • Pharmaco-Economics

    Cost-effectiveness of interferon-α2 as adjuvant therapy in malignant melanoma

    LAFUMA A, Grob JJ

    Expert Opin Pharmacother ; 4(3):343-349

  • Pharmaco-Economics

    Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection

    PECHEVIS M, KHOSHNOOD B, BUTEAU L, DURAND I, PIQUARD Y, LAFUMA A

    Vaccine ; 21: 3556-3564